These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 10453958)

  • 1. Serum level of interleukin-4 is a possible marker of therapeutic response to interferon treatment in patients with chronic hepatitis C.
    Higashi N; Nakamuta M; Motomura K; Enjoji M; Sakai H; Nawata H
    J Hepatol; 1999 Aug; 31(2):383. PubMed ID: 10453958
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of Th1/Th2 cytokines in serum on the pathogenesis of chronic hepatitis C and the outcome of interferon therapy.
    Zhang L; Hao CQ; Miao L; Dou XG
    Genet Mol Res; 2014 Nov; 13(4):9747-55. PubMed ID: 25501184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct-acting antiviral-based triple therapy on alpha-fetoprotein level in chronic hepatitis C patients.
    Takayama K; Furusyo N; Ogawa E; Ikezaki H; Shimizu M; Murata M; Hayashi J
    World J Gastroenterol; 2015 Apr; 21(15):4696-706. PubMed ID: 25914481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The importance of the definition of early virological response for predicting treatment efficacy for chronic hepatitis C.
    Yu ML
    Hepatology; 2011 Apr; 53(4):1403; author reply 1403. PubMed ID: 21480349
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical outcome to interferon therapy in chronic hepatitis C: insights from mechanistic studies.
    Beard MR
    Antivir Ther; 2004 Oct; 9(5):637-9. PubMed ID: 15535401
    [No Abstract]   [Full Text] [Related]  

  • 6. Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study.
    Terrier B; Lapidus N; Pol S; Serfaty L; Ratziu V; Asselah T; Thibault V; Souberbielle JC; Carrat F; Cacoub P
    World J Gastroenterol; 2015 May; 21(18):5647-53. PubMed ID: 25987791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic Hepatitis C Infection in Children.
    Pham YH; Rosenthal P
    Adv Pediatr; 2016 Aug; 63(1):173-94. PubMed ID: 27426900
    [No Abstract]   [Full Text] [Related]  

  • 8. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-α-2a and ribavirin.
    Lange CM; von Wagner M; Bojunga J; Berg T; Farnik H; Hassler A; Sarrazin C; Herrmann E; Zeuzem S
    Eur J Gastroenterol Hepatol; 2010 Nov; 22(11):1303-7. PubMed ID: 20729742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.
    Bernabucci V; Ciancio A; Petta S; Karampatou A; Turco L; Strona S; Critelli R; Todesca P; Cerami C; Sagnelli C; Rizzetto M; Cammà C; Villa E
    World J Gastroenterol; 2014 Nov; 20(44):16726-33. PubMed ID: 25469044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of HCV-specific sequences in chronic myopathy with hepatitis C: improvement with interferon-alpha 2A therapy.
    Sola P; Galassi G; Merelli E; Ferrari MG; Sorgato P; Ghini M
    Eur Neurol; 1999; 42(3):181-3. PubMed ID: 10529547
    [No Abstract]   [Full Text] [Related]  

  • 12. Viral response guided therapy for hepatitis C in the approaching era of direct acting anti-viral agents.
    Berzsenyi MD; Roberts SK
    J Gastroenterol Hepatol; 2010 Apr; 25(4):655-6. PubMed ID: 20492322
    [No Abstract]   [Full Text] [Related]  

  • 13. Sustained viral response after interferon-based therapy in chronic hepatitis C: more evidence to support a life-long cure.
    McGreal N; Jensen DM
    Liver Int; 2009 Apr; 29(4):481-2. PubMed ID: 19323778
    [No Abstract]   [Full Text] [Related]  

  • 14. Serum lipid profile and chronic hepatitis C virus.
    Purnak T; Efe C; Beyazit Y; Ozaslan E
    Hepatology; 2011 Feb; 53(2):716-7. PubMed ID: 20890943
    [No Abstract]   [Full Text] [Related]  

  • 15. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
    Papastergiou V; Stampori M; Lisgos P; Pselas C; Prodromidou K; Karatapanis S
    Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):798-805. PubMed ID: 23395996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum visfatin is correlated with disease severity and metabolic syndrome in chronic hepatitis C infection.
    Huang JF; Huang CF; Yu ML; Dai CY; Huang CI; Yeh ML; Hsieh MH; Yang JF; Hsieh MY; Lin ZY; Chen SC; Chuang WL
    J Gastroenterol Hepatol; 2011 Mar; 26(3):530-5. PubMed ID: 21332548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Chronic hepatitis C virus infection: clinical picture and treatment possibilities].
    Annicchiarico BE; Siciliano M; Gasbarrini A
    G Ital Nefrol; 2012; 29 Suppl 54():S103-8. PubMed ID: 22388839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-21R gene polymorphisms and serum IL-21 levels predict virological response to interferon-based therapy in Asian chronic hepatitis C patients.
    Hsu CS; Hsu SJ; Liu WL; Chen CL; Liu CJ; Chen PJ; Chen DS; Kao JH
    Antivir Ther; 2013; 18(4):599-606. PubMed ID: 23296193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Menopause, and not age, is a critical factor associated with a worse response to antiviral therapy in women affected by chronic hepatitis C.
    Gitto S; Karampatou A; Andreone P; Villa E
    Int J Infect Dis; 2012 Feb; 16(2):e149. PubMed ID: 22209229
    [No Abstract]   [Full Text] [Related]  

  • 20. Optimal follow-up time to determine the sustained virological response in patients with chronic hepatitis C receiving pegylated-interferon and ribavirin.
    Namikawa M; Kakizaki S; Yata Y; Yamazaki Y; Horiguchi N; Sato K; Takagi H; Mori M
    J Gastroenterol Hepatol; 2012 Jan; 27(1):69-75. PubMed ID: 21649727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.